Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset

Por Paul J. Wichgers Schreur, Petra Mooij, Gerrit Koopman, Babs E. Verstrepen, Zahra Fagrouch, Daniella Mortier, Nikki van Driel, Jet Kant, Sandra van de Water, Willy M. Bogers, Carine Punt, Lucien van Keulen, Ernst J. Verschoor, Jeroen Kortekaas
Publicado em 2022-05-01

Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile

Por Thomas P. Monath, Jeroen Kortekaas, Douglas M. Watts, Rebecca C. Christofferson, Angelle Desiree LaBeaud, Brian B Gowen, Clarence J. Peters, Darci R. Smith, Robert Swanepoel, John C. Morrill, Thomas G. Ksiazek, Phillip R Pittman, Stuart T. Nichol, Brian H. Bird, George Bettinger
Publicado em 2020-08-01